Sign In
Buy TRML
$47.98
+0 (+0%)
At Close: Jan 27, 2026
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November
Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting
10:29am, Sunday, 13'th Oct 2024
Tourmaline Bio's Pacibekitug shows promise in treating thyroid eye disease, with pivotal phase 2b data expected in 2025 and a phase 3 study starting in 2024. The 7 major thyroid eye disease markets ar
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
07:30am, Friday, 11'th Oct 2024
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve th
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
07:30am, Tuesday, 08'th Oct 2024
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance a
Tourmaline Bio to Present at Upcoming Investor Conferences
07:45am, Tuesday, 03'rd Sep 2024
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
07:30am, Thursday, 08'th Aug 2024
– First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – – On track to initiate a pivotal Phase 3 trial evaluat
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
04:30pm, Friday, 02'nd Aug 2024
Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and monthly subcutaneous administ
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
08:05am, Thursday, 27'th Jun 2024
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve th
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
07:10am, Thursday, 23'rd May 2024
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve th
– First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk and chronic kidney disease – – Topline data anticipated
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
07:00am, Monday, 13'th May 2024
– Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Drug application (IND) for clinical development program in Atherosclerotic Cardiovascular Dise
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
07:00am, Tuesday, 19'th Mar 2024
– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial
Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going
09:51am, Friday, 15'th Mar 2024
Tourmaline Bio, Inc. (TRML) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Tourmaline Bio to Present at Upcoming Investor Conferences
07:30am, Tuesday, 27'th Feb 2024
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve t
What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing'
09:51am, Thursday, 08'th Feb 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Tourmaline Bio, Inc. (TRML) could be a great choice. It is one of the several stocks that passed through our "R
